Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.
You may also be interested in...
Medicare Use Of Gross Rx Prices In Negotiation Picks Would Limit Savings, Erode Rebates – Payers
United Health Group and CVS strongly object to CMS’s proposed approach to selecting Part D drugs for price negotiation. United Health suggests the agency's method of announcing it will use gross, instead of net, costs could constitute a violation of the Administrative Procedure Act.
Industry Stakeholders Debate Ways To Make Medicare Price Negotiation Policies Palatable
Pharma leaders and stakeholders discussed industry priorities related to the implementation of the Inflation Reduction Act during the BIO CEO and Investor Conference.
Bipartisan Bills To Promote Drug Competition A Step Closer To Completion
The Preserving Access to Affordable Generics and Biosimilars Act and the Stop STALLING Act are both a step closer to becoming law after passing voice votes in the Senate Judiciary Committee.